The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis

AIM: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for glycaemic management in adults with type 2 diabetes (T2D). Oral semaglutide administration can help decrease glycated haemoglobin (HbA1c) and body weight in people with uncontrolled T2D. We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhindi, Yousef, Avery, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260263/
https://www.ncbi.nlm.nih.gov/pubmed/35812819
http://dx.doi.org/10.1016/j.conctc.2022.100944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260263/
https://www.ncbi.nlm.nih.gov/pubmed/35812819
http://dx.doi.org/10.1016/j.conctc.2022.100944

Ejemplares similares